Propofol and halothane binding sites on human serum albumin analysis, but more importantly, is known to play a key role in the pharmacological actions of several general anesthetics.
The importance of serum albumin in anesthetic pharmacology derives from its high concentration in the circulatory system (approximately 0.6 mM in plasma) and from its ability to bind an extraordinarily diverse range of drugs (including most anesthetics), metabolites and fatty acids [for reviews see refs. (9) (10) (11) ]. In several cases more than 50% of a clinically administered general anaesthetic will be bound to serum albumin, and in some cases, such as the intravenous agent propofol, approximately 80% is bound (12).
Consequently, any changes in the interactions between an anesthetic and serum albumin, either by fatty acids or other drugs competing for binding, or by genetic modifications in the protein itself, could result in significant changes in the pharmacologically active concentration of the anesthetic.
Although a high-resolution structure of human serum albumin was published some years ago (13) , the unavailability of the three-dimensional coordinates did not encourage others to extend this work. Curry et al.
subsequently published (14) a high-resolution structure of the protein that identified the principal fatty acid binding sites, and this was followed by the publication of an independent determination of the native structure (15) . The protein is heart-shaped and contains 585 amino acids. It is organised into three homologous domains (labelled I-III) and each domain consists of two sub-domains (A and B) which share common structural elements (Fig. 1 ). In this paper we have used X-ray crystallography to provide high-resolution information on the nature and locations of the principal binding sites for two of the most widely used general anesthetics -the intravenous agent propofol and the inhalational agent halothane (see below). Complexes with halothane were prepared by exposing native crystals to chosen partial pressures of halothane in 1-mm sealed glass capillaries at room temperature. The partial pressure was set by using mixtures of halothane and hexadecane at defined mole ratios. To the extent that halothane and hexadecane mix ideally, the vapour pressure of halothane above such a mixture can, according to Raoult's Law, be taken to be proportional to its mole fraction. The maximum partial pressure of halothane that could be used with native crystals before a significant deterioration in the diffraction patterns was observed was 15% of the saturated vapour pressure (SVP) which would correspond to a partial pressure of 5% atm, or 2.6 mM in free aqueous solution.
To prepare the halothane-myristate complex, crystals with myristate were first prepared (14) before exposure to halothane, as described above. In the presence of myristate we found that a much higher concentration of halothane could be used (60% of the SVP, which would correspond to a partial pressure of 20% atm, or 10.5 mM in free aqueous solution) before lattice disorder in the crystals reduced the resolution of the diffraction patterns.
Data collection and processing -Data were collected to high resolution at the synchrotrons in Daresbury (SRS, UK) and in Hamburg (DESY, Germany). At Daresbury (beamline 9.6), short exposure times (2 -3 seconds) were used in order to minimise radiation damage which was evident with longer exposures. In Hamburg (beamline X-11) the exposure times were 20 -30 Propofol and halothane binding sites on human serum albumin seconds. All data was processed using MOSFLM (Andrew Leslie, personal communication). Details of the data collection are given in Table 1 .
Structure determination and model refinement -The structure of native HSA was determined using molecular replacement with the program AMoRe (17).
The co-ordinates of the search model were those of "molecule A" in the 2.5 Å structure of HSA (Brookhaven accession number 1AO6) recently determined by Sugio and colleagues (15) .
Rigid-body refinement was carried out using the program X-PLOR (18) followed by restrained least squares crystallographic refinement. For the structure containing both halothane and myristate the HSA co-ordinates of the previously determined HSA-myristate structure (14) were used prior to
rigid-body refinement. The co-ordinates for propofol were taken from the Cambridge Structural Database (19) and those for halothane were calculated assuming standard stereochemistry. At the resolution of our data the two enantiomers of halothane would have been indistinguishable and we arbitrarily chose to model the R enantiomer.
After the addition of water molecules, and fatty acid and anesthetic molecules where appropriate, all of the refined models had good stereochemistry (Table 2 ) with no main-chain dihedral angles lying in disallowed regions of the Ramachandran plot (not shown). Co-ordinates and structure factors have been deposited in the Protein Data Bank; ID codes are given in Table 2 .
In the absence of fatty acids HSA crystallized in a P1 space-group with unit cell dimensions ( Table 1 ) that have not been observed before despite the fact that our crystallization conditions were similar to those used by others (13, 15) . The native HSA structure that we have determined is essentially identical to those previously published with only minor differences in the flexible subdomain IIIB (Fig. 1A) , due no doubt to differences in crystal packing. For comparison, Fig. 1B shows the HSA structure in the presence of myristate (14, 20) and the locations of eight fatty acid binding sites. which co-ordinates the fatty acid carboxyl group).
The second propofol molecule (Fig. 2C , Table 3 HAL3 makes numerous close, mainly apolar, interactions within the binding pocket (Table 4 and in the absence of fatty acid and up to 20% atm. in the presence of fatty acid.
Only above these concentrations did we see evidence of crystal disorder, but this could have been a consequence crystal contacts being disrupted rather than due to a conformational change in the protein.
It has been shown (21) that inhalational anesthetics shift the denaturation temperature of BSA to higher temperatures (presumably as a consequence of the anesthetics binding to the folded rather than the unfolded state) and it has also been shown (22) However, although the HSA/myristate/halothane structure does have an average temperature factor that is significantly lower than the structure with myristate alone, the amino acids directly in contact with the anesthetics have temperature factors reduced to the same extent as those amino acids which do not contribute to binding interactions.
Propofol binds at two sites, one in subdomain IIIA and one in subdomain IIIB. In both cases the aromatic ring lies within an apolar pocket, with the phenolic hydroxyl group making a hydrogen bond, in the one case (IIIA) with a main-chain carbonyl oxygen and in the other case (IIIB) with a serine hydroxyl (Fig. 2) . Both propofol molecules would compete for fatty-acid binding: FA3 and possibly FA4 for the molecule in IIIA, and FA5 for the molecule in IIIB. The propofol molecule in IIIB not only binds weaker than the molecule in IIIA (because electron density for this molecule was the first to disappear when the propofol concentration was reduced) but it also binds in a site that almost certainly accommodates the most tightly binding fatty acid (23, 24) . For these reasons one can safely conclude that, at pharmacologically relevant concentrations of propofol in the blood (which are many times lower than the concentrations present in our crystals), only a single propofolbinding site would be occupied (the site in subdomain IIIA). This site in subdomain IIIA has previously been identified crystallographically (13) (27) or that propofol causes protein unfolding which results in the absence of any saturable sites (12). It is possible that these binding studies were somehow confounded by the presence of fatty acids (no particular precautions were taken to exclude them) and more work is clearly needed to resolve the apparent discrepancy between these binding studies and our crystallographic results.
At the "low" halothane concentration and in the absence of fatty acid, only three halothane binding sites were well-occupied (HAL1, HAL2 and HAL3).
However, we could not discern any key features of these binding sites that distinguished them from the lower-affinity sites that were occupied at the higher halothane concentration. All of the binding sites were predominantly apolar, although most also showed evidence of significant polar interactions between charged or polar amino acids and the polarisable halogen atoms, particularly the bromine. The possible importance of polar interactions between proteins and halogenated compounds has been noted before (3, 28) and the likelihood that general anaesthetic binding sites are amphiphilic in nature has been stressed by our group (29, 30) and others (31-33).
Interestingly, as was the case with propofol, all of the halothane molecules bound within pre-formed pockets or clefts. Furthermore (leaving aside halothane HAL8, whose binding site was artefactually formed by crystal contacts) all of the binding sites were also binding sites for fatty acids.
Indeed, in the crystal structure at the high halothane concentration, and in the presence of myristate, the fatty acid has clearly been displaced in sites FA6
(by HAL1, HAL2 and HAL4), FA7 (by HAL5 and HAL6) and FA8 (by HAL7).
This is entirely consistent with the work of Dubois and Evers (5, 6) on the related protein BSA that showed halothane and other volatile anesthetics competed with fatty acids for binding. In addition, the two halothane molecules HAL5 and HAL6 bind within a site which has been identified (13) as a key drug-binding locus on HSA ["site I" of Sudlow et al., (25, 26) ].
Although halothane binding to HAL7 can displace myristate bound to FA8, this site is not occupied by fatty acids with longer chains (20) Which of the halothane sites are pharmacologically relevant? This is a difficult question to answer with certainty. The "low" halothane concentration we used (5% atm.) was still significantly higher than the maximum concentration likely to be used for maintenance of anesthesia, so those binding sites which were only populated at the higher concentration (HAL4, HAL5 and HAL6) are most unlikely to be important. However, all three of the halothane molecules which bind at the lower concentration (HAL1, HAL2 and HAL3) are potentially displaceable by fatty acid, and between 0.1 and 2 molecule of fatty acid is thought to bind under normal physiological conditions. The halothane molecules HAL1 and HAL2 are probably less susceptible to displacement than HAL3 because in the myristate structure the halothane molecules HAL1 and HAL2 were able to displace the Propofol and halothane binding sites on human serum albumin fatty acid FA6 while, in contrast, the fatty acid FA3 was able to prevent the binding of halothane HAL3. In addition, other evidence (20) suggests that FA3 binds more tightly than FA6. Finally, it might be that there is sufficient fatty acid in the blood to induce the conformational change that results in the formation of the binding site for HAL7 which would also make this site (in addition to those for HAL1, HAL2 and HAL3) potentially relevant pharmacologically.
Because of the promiscuous nature of HSA-drug interactions, the possibility that the free, pharmacologically active, concentrations of coadministered drugs could be affected by their competing for common binding sites on the protein has often been considered (11) . For example, the volatile anesthetic enflurane has been shown (36) to displace diazepam from HSA in vitro, and the in vivo pharmacokinetics of thiopental are known to be significantly affected (37) by the presence of halothane. Our finding that propofol binds with highest affinity to a site in subdomain IIIA that can also bind a benzodiazepine (13) suggests that there might be a significant interaction between these drugs (which are often co-administered). However, a common binding site does not guarantee a pharmacologically relevant interaction. While a high percentage of both drugs may be bound to HSA, for either drug the percentage of HSA molecules that are involved in binding could still be very small (because the plasma concentration of HSA is very much greater than the total drug concentration). Indeed, a brief report (12) concluded that diazepam did not displace bound propofol; nonetheless this potential interaction has yet to be extensively studied. Table 3 ). Table 4 ). Note that in D) only 11 of the 14 carbon atoms of myristate are shown because, due to disorder, the terminal carbons were not observed in the electron density map.
